Home Newsfeeds William Blair Initiates Coverage On ARS Pharmaceuticals with Outperform Rating

William Blair Initiates Coverage On ARS Pharmaceuticals with Outperform Rating

William Blair analyst Tim Lugo initiates coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform rating.

byBenzinga Newsdesk

January 4, 2023

1 minute read

William Blair analyst Tim Lugo initiates coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform rating.

Charlie Munger’s Apple Confidence, Raskin Takes A Dig At Santos, Peter Schiff’s Inflation Warning And More: Top Stories From This Weekend You Shouldn’t Miss

By Benzinga Neuro

November 6, 6:03 AM

The weekend was rife with interesting stories that kept the markets buzzing. From Charlie Munger’s unwavering belief in…

AAPL

Apple’s AI Strategy Could Trigger Three-Year iPhone Sales Boost, Says Top Tech Bull: ‘Don’t Overthink It’

By Ananya Gairola

June 7, 11:57 PM

Gene Munster, managing partner at Deepwater Asset Management, suggests that Apple's AI strategy could trigger a three-year iPhone upgrade cycle, potentially boosting the company's sales significantly.

AAPL

AbbVie New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary And All Secondary Endpoints In An Open-Label Head-To-Head Atopic Dermatitis Study; Achieved Both A 90% Or Greater Reduction In Eczema Area And Severity Index And A Wors…

By Benzinga Newsdesk

April 25, 8:09 AM

Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 161LEVEL UP, a Phase 3b/4

ABBV